Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 4,841 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 4,841 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $201,191.96. Following the completion of the transaction, the chief executive officer now directly owns 603,886 shares of the company’s stock, valued at $25,097,502.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Twist Bioscience Trading Up 5.3 %

Twist Bioscience stock opened at $45.42 on Thursday. The stock has a fifty day moving average price of $43.64 and a 200 day moving average price of $45.43. Twist Bioscience Co. has a 52 week low of $15.85 and a 52 week high of $60.90. The firm has a market capitalization of $2.66 billion, a P/E ratio of -11.89 and a beta of 1.78.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the period. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. lifted its position in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Robert W. Baird lifted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.